UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

Journal of clinical oncology, 2010-11, Vol.28 (33), p.4877-4883

2010

Volltextzugriff (PDF)

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Cancer discovery, 2022-05, Vol.12 (5), p.1233-1247

2022

Volltextzugriff (PDF)

Molecular Pathways: Blockade of the PRLR Signaling Pathway as a Novel Antihormonal Approach for the Treatment of Breast and Prostate Cancer

Clinical cancer research, 2013-04, Vol.19 (7), p.1644-1650

2013

Volltextzugriff (PDF)

Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma

Journal of translational medicine, 2010-09, Vol.8 (1), p.89-89, Article 89

2010

Volltextzugriff (PDF)

Combination of Oxaliplatin Plus Irinotecan in Patients With Gastrointestinal Tumors: Results of Two Independent Phase I Studies With Pharmacokinetics

Journal of clinical oncology, 1999-06, Vol.17 (6), p.1751-1759

1999

Volltextzugriff (PDF)

NRG1 fusion-driven cancers: A systematic literature review and meta-analysis

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e15605-e15605

2020

Volltextzugriff (PDF)

SY4-10. Zenocutuzumab in pancreas cancer and other solid tumors with NRG1 fusions

Journal of the Japan Pancreas Society, 2021, Vol.36 (3), p.A164-A164

2021

Volltextzugriff (PDF)

Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor

JCO precision oncology, 2022-08 (6)

2022

Volltextzugriff (PDF)

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration‐Resistant Prostate Cancer

The oncologist (Dayton, Ohio), 2016-05, Vol.21 (5), p.535-536i

2016

Volltextzugriff (PDF)

Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.62-62

2021

Volltextzugriff (PDF)

Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.105-105

2022

Volltextzugriff (PDF)

Abstract OT2-15-01: Updated analysis of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) metastatic breast cancer (MBC) who progressed on previous anti-HER2 ADCs

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-15-01-OT2-15-01

2022

Volltextzugriff (PDF)

Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors

Clinical pharmacokinetics, 2020-07, Vol.59 (7), p.875-884

2020

Volltextzugriff (PDF)

Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P185-P185

2021

Volltextzugriff (PDF)

Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3003-3003

2021

Volltextzugriff (PDF)

Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.PR02-PR02

2019

Volltextzugriff (PDF)

A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS3654-TPS3654

2020

Volltextzugriff (PDF)

Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3093-3093

2020

Volltextzugriff (PDF)

Irinotecan plus Oxaliplatin: a Promising Combination for Advanced Colorectal Cancer

Clinical colorectal cancer, 2001-11, Vol.1 (3), p.149-153

2001

Volltextzugriff (PDF)

Abstract CT156: MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced gastric/esophageal adenocarcinoma (GEA)

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT156-CT156

2023

Volltextzugriff (PDF)

Abstract CT012: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT012-CT012

2023

Volltextzugriff (PDF)

Abstract B16: NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapy

Cancer research (Chicago, Ill.), 2015-07, Vol.75 (14_Supplement), p.B16-B16

2015

Volltextzugriff (PDF)

Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS -mutant cutaneous melanoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9500-9500

2016

Volltextzugriff (PDF)

IS3-6. Efficacy and safety of zenocutuzumab in advanced pancreatic cancer and other solid tumors harboring NRG1 fusions

Japanese Journal of Lung Cancer, 2021-10, Vol.61 (6), p.543-543

2021

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(41)
Buchkapitel
(3)

Sprache

Englisch
(42)
Japanisch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Molecular Pathways: Blockade of the PRLR Signaling Pathway as a Novel Antihormonal Approach for the Treatment of Breast and Prostate Cancer

Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma

Combination of Oxaliplatin Plus Irinotecan in Patients With Gastrointestinal Tumors: Results of Two Independent Phase I Studies With Pharmacokinetics

NRG1 fusion-driven cancers: A systematic literature review and meta-analysis

SY4-10. Zenocutuzumab in pancreas cancer and other solid tumors with NRG1 fusions

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration‐Resistant Prostate Cancer

Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC)

Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers

Abstract OT2-15-01: Updated analysis of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) metastatic breast cancer (MBC) who progressed on previous anti-HER2 ADCs

Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors

Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma

Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions

Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers

A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors

Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs

Irinotecan plus Oxaliplatin: a Promising Combination for Advanced Colorectal Cancer

Abstract CT156: MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced gastric/esophageal adenocarcinoma (GEA)

Abstract CT012: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)

Abstract B16: NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapy

Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS -mutant cutaneous melanoma

IS3-6. Efficacy and safety of zenocutuzumab in advanced pancreatic cancer and other solid tumors harboring NRG1 fusions

Suchergebnisse filtern